# Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)

> **NCT07481747** · PHASE3 · RECRUITING · sponsor: **Hudson Biotech** · enrollment: 2539 (estimated)

## Conditions studied

- Obesity
- Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities

## Interventions

- **DRUG:** Tirzepatide
- **DRUG:** Placebo
- **BEHAVIORAL:** Reduced-calorie diet

## Key facts

- **NCT ID:** NCT07481747
- **Lead sponsor:** Hudson Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-02
- **Primary completion:** 2027-02-14
- **Final completion:** 2028-03-17
- **Target enrollment:** 2539 (ESTIMATED)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07481747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07481747, "Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07481747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*